Geographic differences in time to culture conversion in liquid media: Tuberculosis trials Consortium Study 28. Culture conversion is delayed in Africa

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Mac Kenzie, William R ^a   Heilig, Charles M ^a   Bozeman, Lorna ^a   Johnson, John L ^b   Muzanye, Grace ^c   Dunbar, Denise ^d   Jost Jr , Kenneth C ^d   Diem, Lois ^a   Metchock, Beverly ^a   Eisenach, Kathleen ^e   Dorman, Susan ^f   Goldberg, Stefan ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ACID FAST BACTERIUM; AFRICA; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIQUID CULTURE; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; RACE DIFFERENCE; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS;

AFRICA; CELL CULTURE TECHNIQUES; CONTINENTAL POPULATION GROUPS; CULTURE MEDIA; GEOGRAPHY; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PROBABILITY; SPECIMEN HANDLING; SPUTUM; TIME FACTORS; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79954525292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018358     Document Type: Article

References (28)

1. Mitchison DA, (1993) Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. American Review of Respiratory Disease 147: 1062-1063.
2. Telzak EE, Fazal BA, Turett GS, Justman JE, Blum S, (1998) Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clinical Infectious Diseases 26: 775-776.
3. Guler M, Uensal E, Dursun B, Aydin O, Capan N, (2007) Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. International Journal of Clinical Practice 61: 231-235.
4. Maalej S, Belhaoui N, Bourguiba M, Mahouachi R, Chtourou A, et al. (2009) Pulmonary tuberculosis and diabetes Retrospective study of 60 patients in Tunisia. Presse Medicale 38: 20-24.
5. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W, (2009) Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. American Journal of Tropical Medicine and Hygiene 80: 634-639.
6. Salihu HM, Aliyu MH, Ratard R, Pierre-Louis BJ, (2003) Characteristics associated with reported sputum culture conversion in the era of re-emergent Mycobacterium tuberculosis in the State of North Carolina, 1993-1998. International Journal of Tuberculosis and Lung Disease 7: 1070-1076.
7. Abal AT, Jayakrishnan B, Parwer S, El Shamy A, Abahussain E, et al. (2005) Effect of cigarette smoking on sputum smear conversion in adults with active pulmonary tuberculosis. Respiratory Medicine 99: 415-420.
8. Slam K, Chiang CY, Enarson DA, Hassmillert K, Fanning A, et al. (2007) Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease 11: 1049-1061.
9. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, et al. (2009) Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine 180: 273-280.
10. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Eagle M, et al. (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 174: 331-338.
11. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, et al. (2010) Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations. Antimicrobial Agents and Chemotherapy 54: 4192-4200.
12. Harrington DP, Fleming TR, (1982) A class of rank test procedures for censored survival-data Biometrika 69: 553-566.
13. Dunlap NE, Bass J, Fujiwara P, Hopewell P, Horsburgh CR, et al. (2000) Diagnostic standards and classification of tuberculosis in adults and children. American Journal of Respiratory and Critical Care Medicine 161: 1376-1395.
14. WHO, eds. (1998) Laboratory Services in Tuberculosis Control. WHO/TB 98:258 Geneva, Switzerland WHO.
15. Molhuizen HOF BA, Schouls LM, van Embden JDA, (1998) Rapid detection and simultaneous strain differentiation of Mycobacterium tuberculosis complex bacteria by spoligotyping. Methods Mol Biol 101: 381-394.
16. Cowan LS, Diem L, Brake MC, Crawford JT, (2004) Transfer of a Mycobacterium tuberculosis genotyping method, spoligotyping, from a reverse line-blot hybridization, membrane-based assay to the Luminex multianalyte profiling system. Journal of Clinical Microbiology 42: 474-477.
17. Cowan LS, Diem L, Monson T, Wand P, Temporado D, et al. (2005) Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States. Journal of Clinical Microbiology 43: 688-695.
18. van Embden JDA CM, Crawford JT, et al. (1993) Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31: 406-409.
19. Fox W HP, Sutherland I, Williams AW, (1956) A comparison of acute extensive pulmonary tuberculosis and its response to chemotherapy in Britain and Uganda. Tubercle 37: 435-450.
20. Rekha VVB, Balasubramanian R, Swaminathan S, Ramachandran R, Rahman F, et al. (2007) Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. Indian Journal of Medical Research 126: 452-458.
21. CLSI, (2008) Laboratory Detection and Identification of Mycobacteria; Approved Guideline. Wayne, PA Clinical and Laboratory Standards Institute.
22. Burdz TVN, Wolfe J, Kabani A, (2003) Evaluation of sputum decontamination methods for Mycobacterium tuberculosis using viable colony counts and flow cytometry. Diagnostic Microbiology and Infectious Disease 47: 503-509.
23. Peres RL, Maciel EL, Morais CG, Ribeiro FCK, Vinhas SA, et al. (2009) Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. International Journal of Tuberculosis and Lung Disease 13: 1572-1575.
24. Zhang Y, (2004) Persistent and dormant tubercle bacilli and latent tuberculosis. Frontiers in Bioscience 9: 1136-1156.
25. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 12: 128-138.
26. Joloba ML, Johnson JL, Namale A, Morrissey A, Assegghai AE, et al. (2000) Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 4: 528-536.
27. Johnson J, Hadad D, Dietze R, (2009) Shortening Treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180: 558-563.
28. Conde MB, Efron A, Laredo C, De Souza GRM, Graca NP, et al. (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373: 1183-1189.